1 400

Cited 5 times in

Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer

 Sang Joon Shin  ;  Hei-Cheul Jeung  ;  Joong Bae Ahn  ;  Sun Young Rha  ;  Nae Choon Yoo  ;  Jae Kyung Roh  ;  Sung Hoon Noh  ;  Hyun Cheol Chung 
 CANCER LETTERS, Vol.270(2) : 269-276, 2008 
Journal Title
Issue Date
Adenocarcinoma/drug therapy* ; Adenocarcinoma/immunology ; Adenocarcinoma/pathology ; Adult ; Aged ; Antigens, CD34/analysis* ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Biomarkers/analysis ; Bone Marrow Cells/drug effects* ; Bone Marrow Cells/immunology ; Cell Line, Tumor ; Cell Movement/drug effects* ; Cell Survival/drug effects ; Cells, Cultured ; Disease-Free Survival ; Docetaxel ; Endothelial Cells/drug effects* ; Endothelial Cells/immunology ; Female ; Fluorouracil/administration & dosage ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Humans ; Infusions, Intravenous ; Leucovorin/administration & dosage ; Male ; Maximum Tolerated Dose ; Middle Aged ; Stem Cells/drug effects* ; Stem Cells/immunology ; Stomach Neoplasms/drug therapy* ; Stomach Neoplasms/immunology ; Stomach Neoplasms/pathology ; Taxoids/administration & dosage ; Time Factors ; Treatment Outcome
Gastric cancer ; Biomarker ; CD34+ cells
We investigated whether the level of bone marrow-derived progenitor cells and mature endothelial cells could be used as predictors of clinical outcome in patients receiving taxotere-based chemotherapy for advanced gastric cancer. Peripheral blood mononuclear cells were obtained from 49 gastric cancer patients who received taxotere combined with 5-FU and leucovorin and prophylactic G-CSF treatment. To categorize the cells, the cell markers CD34, vWF, P1H12, and CD31 were stained. Changes in these cells were examined before and after chemotherapy, and the clinical significance of these changes to response prediction and prognosis were investigated. Before the second cycle of chemotherapy, the number of CD34+/vWF+ and CD34+ cells was higher in non-responders as compared to the responders. Patients with > or =6.2 CD34+/vWF+ cells/ml had a shorter progression free survival (3.7 months) as against patients with <6.2 CD34+/vWF+/ml (6.0 months, p = 0.076). Patients with > or =5.8 CD34+ cells/ml had shorter progression free survival (4.0 months) than patients with <5.8 CD34+ cells/ml (6.1 months, p = 0.046). In an ex vivo pharmacokinetic study, the maximum inhibition (I(max)) for HUVEC and YCC3 cells was 13.0 +/- 6.6% and 74.0 +/- 2.0%, respectively. The time to reach I(max) (T(max)) was 72 h in all HUVEC cells and 0.5 hours in YCC3 cells. We suggested that CD34+/vWF+ and CD34+ cells can be used as a biomarker for prediction and CD34+ cells for prognosis.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Noh, Sung Hoon(노성훈) ORCID logo https://orcid.org/0000-0003-4386-6886
Roh, Jae Kyung(노재경)
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Shin, Sang Joon(신상준) ORCID logo https://orcid.org/0000-0001-5350-7241
Ahn, Joong Bae(안중배) ORCID logo https://orcid.org/0000-0001-6787-1503
Yoo, Nae Choon(유내춘)
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
Jeung, Hei Cheul(정희철) ORCID logo https://orcid.org/0000-0003-0952-3679
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.